Influence of Several Compounds and Drugs on the Renal Uptake of Radiolabeled Affibody Molecules

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Affibody molecules are the most studied class of engineered scaffold proteins (ESPs) in radionuclide molecular imaging. Attempts to use affibody molecules directly labelled with radiometals for targeted radionuclide therapy were hampered by the high uptake and retention of radioactivity in kidneys. Several promising strategies have been implemented to circumvent this problem. Here, we investigated whether a pharmacological approach targeting different components of the reabsorption system could be used to lower the uptake of [99mTc]Tc-ZHER:2395 affibody molecule in kidneys. Pre-injection of probenecid, furosemide, mannitol or colchicine had no influence on activity uptake in kidneys compared to the control group. Mice pre-injected with maleate and fructose had 33% and 51% reduction in the kidney-associated activity, respectively, compared to the control group. Autoradiography images showed that the accumulation of activity after [99mTc]Tc-ZHER2:2395 injection was in the renal cortex and that both maleate and fructose could significantly reduce it. Results from this study demonstrate that pharmacological intervention with maleate and fructose was effective in reducing the kidney uptake of affibody molecules. A presumable mechanism is the disruption of ATP-mediated cellular uptake and endocytosis processes of affibody molecules by tubular cells.

Detaljer

Författare
Enheter & grupper
Externa organisationer
  • Uppsala universitet
  • Tomsk Polytechnic University
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Urologi och njurmedicin
  • Radiologi och bildbehandling

Nyckelord

Originalspråkengelska
Artikelnummer2673
TidskriftMolecules (Basel, Switzerland)
Volym25
Utgåva nummer11
StatusPublished - 2020
PublikationskategoriForskning
Peer review utfördJa